Mankind Pharma shareholders have approved the reappointment of key leadership figures and adopted the financial statements for the fiscal year ended March 31, 2026, at the company’s Thirty-Fifth Annual General Meeting (AGM). The meeting, held via video conferencing on August 4, 2026, passed all ordinary resolutions placed before members, including the ratification of cost auditor remuneration for FY27.

The proceedings were conducted in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Ramesh Juneja, Executive Chairman, presided over the meeting after Mr. Rajeev Juneja, Vice Chairman and Managing Director, was unable to attend due to bereavement in the family. A total of 143 members participated through video conferencing, with remote e-voting facilitated by CDSL from August 1 to August 3, 2026.

Key Resolutions Passed

Shareholders voted on four ordinary resolutions during the AGM. The most significant outcomes involved the continuity of board leadership and the formal adoption of the company’s financial performance for FY26.

Management Updates and Audit Reports

Mr. Sheetal Arora, CEO & Whole-time Director, provided updates on business operations, while Global Chief Financial Officer Mr. Ashutosh Dhawan presented an overview of the financials for FY26. The Chairman informed members that the Statutory Auditors' Report and Secretarial Auditor's Report contained no qualifications or observations.

Joint Statutory Auditors from S.R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Company were present, along with Secretarial Auditor M/s. Amit Gupta & Associates and Cost Auditor M/s. M. K. Kulshreshta & Associates. The Scrutinizer for the e-voting process was Mohit Chaurasia & Associates.

What the Numbers Show

While specific financial figures were not detailed in the AGM proceedings document, the clean audit reports indicate no material irregularities in the financial statements for FY26. The seamless reappointment of both Rajeev Juneja and Satish Kumar Sharma suggests shareholder confidence in the current management structure despite the absence of the Vice Chairman and Managing Director from the physical proceedings.

Mankind Pharma delivered a robust first-quarter performance for FY27, reporting a consolidated net profit of ₹574 crore, a 29% increase from ₹445 crore in the corresponding period of the previous year. Revenue from operations rose 13% year-on-year to ₹4,031 crore, while EBITDA expanded by 25% to ₹1,060 crore. The results were driven by significant margin expansion, strong growth in domestic chronic therapies, and a 29% surge in international exports. The Board of Directors approved the unaudited financial results on July 30, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company’s operating leverage improved markedly, with EBITDA margins widening by 250 basis points (bps) to 26.3% from 23.8% in Q1FY26. Gross margins also improved by 230 bps to 72.8%, aided by sales price increases, a better mix from higher-margin chronic products, and a favorable base effect from inventory accruals in the prior year. Profit after tax (PAT) margins rose by 170 bps to 14.2%. Basic earnings per share (EPS) stood at ₹13.76, compared to ₹10.62 in the prior year quarter. Cash EPS, adjusted for non-cash items like depreciation and amortization, increased 20.8% YoY to ₹19.2.

Financial Performance Highlights

Standalone net profit was ₹558.49 crore, up from ₹415.27 crore in Q1FY25. Standalone revenue grew to ₹2,964.05 crore from ₹2,569.73 crore. Finance costs declined to ₹110 crore from ₹142 crore in Q4FY26, primarily due to the repayment of a ₹1,250 crore NCD tranche. However, the effective tax rate rose to 25.4% from 17.7% due to the expiry of tax exemptions for its Sikkim plant.

Segmental Breakdown and Business Updates

Domestic business (excluding Consumer Healthcare) grew 11% YoY to ₹3,180 crore, led by double-digit growth in the base business and strong momentum in chronic therapies. Chronic therapies contributed significantly, with cardiac drugs growing 19.4% and anti-diabetic drugs growing 12.7%. The company outperformed the industry prescription market (IPM) in key areas, including respiratory chronic (1.3x IPM growth) and cardiac (1.1x IPM growth). Specific brand performances included 21% growth in the Telmikind family, 30-31% growth in Lipirose and Statpure, and 29% growth in the Glizid brand family. Acute therapies recovered to 10.9% growth, broadly in line with IPM.

Exports surged 29% YoY to ₹605 crore, benefiting from new product launches in the US market, where Mankind has now launched 49 products. Currency movements contributed 12-13% to export growth. The Consumer Healthcare (CH) segment saw modest growth of 4% to ₹246 crore, impacted by the discontinuation of cash-and-carry business to protect general trade margins. However, it gained market share in key brands like Manforce and Prega News. Modern Trade and E-Commerce share increased to 15% from 11% in the prior year quarter, supported by 38% growth in that channel.

Strategic Initiatives and Outlook

Management highlighted a strategic shift towards chronic and specialty therapies, aiming to increase the chronic share to 50% in the medium term, up from 40% currently. The company launched a new division, Vistar, to scale lesser-focused brands. In innovation, Mankind partnered with Denovo Science for an AI-led drug discovery program and acquired the Rivotril brand from Roche, which is valued at ₹20-30 crore with potential for significant growth in the CNS segment.

Net debt reduced to ₹3,377 crore as of June 30, 2026, improving the net debt-to-adjusted EBITDA ratio to 0.9x from 1.1x in FY26. Management remains on track to repay acquisition-related debt by FY28. Capex spend increased to ₹198 crore (4.9% of revenue), lower than the full-year guidance of 6-7%. Working capital days increased to 52 days from 48 days due to higher inventory levels, which management expects to rationalize in coming quarters.

What the Numbers Show

The divergence between revenue growth (13%) and PAT growth (29%) underscores improved operational efficiency and successful cost management. The 250 bps expansion in EBITDA margins indicates a favorable product mix shift towards higher-margin chronic therapies. While gross margins are healthy at 72.8%, management cautioned about potential compression in subsequent quarters due to rising raw material prices and dollar fluctuations, though they maintain their full-year EBITDA guidance of 25.5-26.5%. Investors should note the ongoing income tax proceedings involving adjustments of ₹1,908.66 crore, which remain a contingent liability despite management’s confidence in their legal position.